Actor portrayals.

SHINGRIX, administered as a 2-dose series, was proven to help prevent shingles in adults 50 years and older.1

Age and additional risk factors for shingles

LEARN ABOUT RISK

Protecting patients starts with a strong recommendation from you

FIND OUT MORE

SHINGRIX delivered >90% efficacy against shingles in adults 50 years and older1

SEE THE DATA

Shingles can strike at any time2

Shingles, a blistering rash that can be excruciatingly painful, is caused by the reactivation of the latent varicella zoster virus (VZV).2,3

 

99.5% of people ≥50 years old are infected with VZV.4,5

 

In 1 in 3 people, the dormant virus reactivates in their lifetime, causing shingles to erupt.4

Patient portrayal.

Starting at 50 years old, shingles risk sharply increases4

Increasing age can lead to a natural decline in VZV-specific immunity4

Incidence rate of herpes zoster by age—United States6,*

Incidence rate of herpes zoster by age in the United States bar graph
LEARN MORE

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles) in adults aged 50 years and older.1

SHINGRIX delivered greater than 90 percent efficacy against shingles regardless of age in those 50 years and older
EXPLORE THE CLINICAL DATA
  • †

    Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years old from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.1,7

CDC recommendations8,9:

SHINGRIX is recommended for the prevention of herpes zoster and related complications‡ for immunocompetent adults ≥50 years old:

  • SHINGRIX is recommended regardless of whether or not they report a prior dose of Zostavax, a shingles vaccine that is no longer available for use in the United States
  • It is not necessary to screen, either verbally or by laboratory serology, for evidence of prior varicella infection


Please visit CDC.gov for full routine shingles vaccination recommendations, including recommendations for immunocompromised adults.

  • ‡

    SHINGRIX is not indicated for the prevention of herpes zoster-related complications.1

Is Arthur at an increased risk of shingles?

PATIENT HISTORY

  • He is 62 years old with diabetes
  • No vaccination for shingles
LEARN MORE
Patient portrayal.

SHINGRIX coadministration with certain other adult vaccines

When your patients' sleeves are up, don't miss the opportunity to help protect them from shingles with SHINGRIX.

EXPLORE COADMINISTRATION INFO

Start the conversation and recommend SHINGRIX today

Access videos, educational events, and downloadable patient and HCP resources.

VIEW RESOURCES

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In postmarketing observational studies, an increased risk of Guillain-Barré syndrome has been observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Prescribing Information for SHINGRIX.
  2. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
  3. Curran D, Matthews S, Boutry C, Lecrenier N, Cunningham AL, Schmader K. Natural history of herpes zoster in the placebo groups of three randomized phase Ill clinical trials. Infect Dis Ther. 2022;11(6):2265-2277.
  4. Clinical overview of shingles (herpes zoster). Centers for Disease Control and Prevention. Reviewed June 27, 2024. Accessed September 7, 2025. https://www.cdc.gov/shingles/hcp/clinical-overview/index.html
  5. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118.
  6. Shingles facts and stats. Centers for Disease Control and Prevention. Reviewed April 12, 2024. Accessed September 7, 2025. https://www.cdc.gov/shingles/data-research/index.html
  7. Data on file. Study 113077 (NCT01165229). GSK Study Register. Study entry at: https://www.gsk-studyregister.com/en/trial-details/?id=113077
  8. Shingles vaccine recommendations. Centers for Disease Control and Prevention. Reviewed October 22, 2024. Accessed September 23, 2025. https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html
  9. Dooling, KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103-108.

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET